Live Analyst Rating Changes 35635 upgrades, downgrades & price-target moves · freshest Wall Street data, updated daily View live feed →
Analyst Tracker/Kerry Holford
BER

Kerry Holford

Berenberg Bank
Wall Street Analyst
★★★☆☆
#2070
on 13Foresight · ranked by our own returns
58%
Success Rate
+0.3%
Average Return
15 of 26 calls profitable · +20.4% vs benchmark
S&P 500 (SPY)
📈 Across the calls we could measure, roughly 58% of Kerry Holford's ratings turned a profit when each position was held for 1 year — averaging +0.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

15 Buy 30 Hold 0 Sell
Kerry's Stock Coverage 15 ratings · 2026-09-30
Company Date Position Consensus ⓘ Price Target ⓘ 1-Yr Return vs S&P 500 ⓘ
GB:0QIU
Novo Nordisk
 Sep 22, 2026 HOLD Hold
+61.1% avg upside
29 analysts
$305.00
20.98% Upside
 · ·
GB:GSK
GlaxoSmithKline
 Sep 15, 2026 HOLD Hold
+4.6% avg upside
26 analysts
$2200.00
18.53% Upside
 -0.8% ·
LLY
Eli Lilly & Co
 Sep 14, 2026 BUY Strong Buy
-8.7% avg upside
49 analysts
$1400.00
18.20% Upside
 +4.0% ·
CH:NOVN
Novartis AG
 Sep 11, 2026 HOLD Buy
-7.9% avg upside
32 analysts
$105.00
13.23% Downside
 +5.2% ·
NVO
Novo Nordisk
 Aug 11, 2026 HOLD Hold
+200.9% avg upside
26 analysts
$47.00
22.78% Upside
 -17.8% ·
PFE
Pfizer
 Aug 05, 2026 HOLD Buy
+17.1% avg upside
45 analysts
$25.00
12.99% Downside
 +10.5% ·
NVS
Novartis
 Jul 27, 2026 HOLD Buy
-4.2% avg upside
24 analysts
$147.00
0.80% Upside
 -6.0% ·
GB:0NZT
UCB SA
 Jul 02, 2026 BUY Strong Buy
+5.8% avg upside
19 analysts
$305.00
43.59% Upside
 · ·
ZLDPF
Zealand Pharma
 Jun 16, 2026 HOLD Buy
+90.3% avg upside
12 analysts
$45.62
8.73% Upside
 -6.7% ·
GSK
GlaxoSmithKline
 Nov 25, 2025 HOLD Hold
-11.8% avg upside
20 analysts
$43.00
12.88% Downside
 +6.3% ·
FR:SAN
Sanofi
 May 16, 2025 BUY Strong Buy
+35.9% avg upside
30 analysts
$120.00
67.84% Upside
 -15.3% ·
FR:EFG
OLYMPIQUE LYONNAIS GROUPE
 Apr 01, 2025 HOLD Hold
+2.0% avg upside
1 analyst
$1.60
1.98% Upside
 -2.4% ·
GB:TIG
Team Internet Group
 Mar 24, 2025 BUY Strong Buy
+363.8% avg upside
3 analysts
$100.00
146.88% Upside
 -47.2% ·
EL
The Estée Lauder Companies
 Mar 24, 2025 HOLD Buy
+14.1% avg upside
33 analysts
$60.00
36.50% Downside
 +7.7% ·
DE:MRK
Merck KGaA
 Apr 16, 2021 HOLD Buy
+0.9% avg upside
34 analysts
$150.00
9.11% Upside
 +28.0% ·
🔒 10 more ratings — with price targets, crowd consensus and our measured returns.
Sign in free to unlock See Pro plans
Free account unlocks every analyst's full coverage table.
Kerry Holford — Frequently Asked Questions
How accurate are Kerry Holford's stock ratings?
Based on the calls 13Foresight could measure, about 58% of Kerry's ratings were profitable over a one-year hold, with an average return of +0.3% per rating, or +20.4% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.
How is Kerry ranked on 13Foresight?
Kerry Holford is currently ranked #2070 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.
Which stocks does Kerry cover?
Kerry most recently has ratings on GB:0QIU, GB:GSK, LLY, CH:NOVN, NVO, PFE, NVS, GB:0NZT, ZLDPF, GSK, FR:SAN, FR:EFG and 3 more. See the full coverage table above for positions, price targets and our measured returns.
Where can I see other analyst ratings?
Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.